Hapbee’s (HAPB) Device, “Choose How You Feel.”
HAPBEE ANNOUNCES LAUNCH OF A SUBSCRIPTION-BASED WELLBEING WEARABLE, PROVIDING MEMBERS THE ABILITY TO CHOOSE 'HOW THEY FEEL'
Proprietary, Research-Backed Band Delivers Control and Peace of...
Citius (CTXR) Announces Results of Mino-Lok Study.
"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected catheter."
LIVE QUOTE
Citius...
Tesla (TSLA) Price Target Upped to $1,000. Passes $500 Billion in Valuation Today.
First Crossing $100 Billion in Value in January, Crossing $527 Today Puts the Valuation at $500 Billion. Why Own Anything Else?
LIVE QUOTE
For those that...
OMNIQ (OMQS) $5.00 Reports $15.8 Million 3Q, up 21%.
OMNIQ Corp. Reports Strong Sales of $15.8 Million for Third Quarter of 2020, up 21% Year over Year
Strong sequential revenue growth of 25 %...
Adding OmniQ (OMQS) $5.00 to the Watch List.
Artificial Intelligence (AI) Fans Take a Peek.
This is our Latest Attempt at Bargain Hunting. Hope it's as Good as the Last One a...
Hapbee (HAPB) Provides Update. Over 1,800 Devices Delivered.
Hapbee Provides Update on Recent Corporate Developments - Manufactured and Shipped Over 1,800 Hapbee Wearables to Early Adopters, Fulfilled All Orders from Successful Indiegogo...
Adding Galaxy Digital (GLXY) $5.19 to Watch List.
Here's your back-door into Bitcoin, which as you are probably aware is on a tear once again (see chart below). News of MicroStrategy (MSTR)...
Telehealth App Hapbee (HAPB) Goes Public and More.
1. Hapbee (HAPB) $0.30, Going Public.2. Saying Goodbye to Immunomedics (IMMU) $86.3. Adding Biosig (BSGM) $2.95, to Watch List.4. Dalrada (DFCO) $0.11, Cancer Screening Test...
Hapbee (HAPB) to Commence Trading on the TSX Venture Exchange.
VANCOUVER, BC, Oct. 28, 2020 /CNW/ - Hapbee Technologies, Inc. (TSXV: HAPB) ("Hapbee" or the "Company"), a wellness technology company developing the revolutionary Hapbee...
Dalrada Cervical Cancer Testing Kit Study.
KEY TAKEAWAYS
Dalrada Corp (DFCO)
LIVE QUOTE
This was admittedly a small test, with only 100 patients. But keep in mind in the first place, this isn't...














